BTIG analyst Justin Zelin downgraded Kura Oncology (NASDAQ: KURA) from Buy to Neutral.The analyst comments "We are downgrading our rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE